Skip to main navigation Skip to search Skip to main content

Erratum: Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications (BioMed Research International (2021) 2021 (9996193) DOI: 10.1155/2021/9996193)

  • Brian Godman
  • , Magdalene Wladysiuk
  • , Stuart McTaggart
  • , Amanj Kurdi
  • , Eleonora Allocati
  • , Mihajlo Jakovljevic
  • , Francis Kalemeera
  • , Iris Hoxha
  • , Anna Nachtnebel
  • , Robert Sauermann
  • , Manfred Hinteregger
  • , Vanda Marković-Peković
  • , Biljana Tubic
  • , Guenka Petrova
  • , Konstantin Tachkov
  • , Juraj Slabý
  • , Radka Nejezchlebova
  • , Iva Selke Krulichová
  • , Ott Laius
  • , Gisbert Selke
  • Irene Langner, András Harsanyi, András Inotai, Arianit Jakupi, Svens Henkuzens, Kristina Garuolienė, Jolanta Gulbinovič, Patricia Vella Bonanno, Jakub Rutkowski, Skule Ingeberg, Øyvind Melien, Ileana Mardare, Jurij Fürst, Sean Macbride-Stewart, Carol Holmes, Caridad Pontes, Corinne Zara, Marta Turu Pedrola, Mikael Hoffmann, Vasileios Kourafalos, Alice Pisana, Rita Banzi, Stephen Campbell, Bjorn Wettermark
  • University of Strathclyde
  • Sefako Makgatho Health Sciences University
  • Universiti Sains Malaysia
  • Jagiellonian University Medical College
  • HTA Consulting
  • Public Health Scotland
  • Hawler Medical University
  • IRCCS Istituto di ricerche farmacologiche Mario Negri - Milano, Bergamo, Ranica
  • Peter the Great St. Petersburg Polytechnic University
  • Hosei University
  • University of Kragujevac
  • University of Namibia
  • University of Medicine Tirana
  • Dachverband der Österreichischen Sozialversicherungen
  • University of Banja Luka
  • Agency for Medicines and Medical Devices of Bosnia and Herzegovina
  • Medical University Sofia
  • State Institute for Drug Control
  • Charles University
  • State Agency of Medicines
  • Wissenschaftliches Institut der AOK (WIdO)
  • Eotvos Lorand University
  • Semmelweis University
  • University for Business and Technology
  • Independant Consultant
  • Vilnius University
  • University of Malta
  • University of Oslo
  • Carol Davila University of Medicine and Pharmacy
  • Health Insurance Institute
  • NHS Greater Glasgow and Clyde
  • NHS Lothian
  • Generalitat de Catalunya
  • Autonomous University of Barcelona
  • Division of Clinical Pharmacology
  • EOPYY-National Organization for the Provision of Healthcare Services
  • Karolinska Institutet
  • University of Manchester
  • Uppsala University

Research output: Contribution to journalComment/debate

Abstract

In the article titled “Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications” [1], the captions of Figures 3 and 4 were incorrect. The corrected captions for Figures 3 and 4 appear below. (Figure Presented). Figure 4: Utilisation of insulin glargine biosimilar (100 IU/ml) as a % of total insulin glargine 100 IU/ml (DDD based) over time across Europe.

Original languageEnglish
Article number9757348
JournalBioMed Research International
Volume2023
DOIs
StatePublished - 2023
Externally publishedYes

Fingerprint

Dive into the research topics of 'Erratum: Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications (BioMed Research International (2021) 2021 (9996193) DOI: 10.1155/2021/9996193)'. Together they form a unique fingerprint.

Cite this